Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK4524101 · 1 trial · 1 indication
ORR is the percentage of participants with an Investigator-assessed confirmed complete response and confirmed partial response to treatment, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
| Arm | Type | Description |
|---|---|---|
| Part 1 - GSK4524101 Monotherapy | EXPERIMENTAL | - |
| Part 1 - GSK4524101 plus Niraparib | EXPERIMENTAL | - |
| Part 1 - GSK4524101 Food Effect Cohort | EXPERIMENTAL | - |
| Part 2 - GSK4524101 plus Niraparib | EXPERIMENTAL | - |
| Part 2 - Niraparib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GSK4524101 | DRUG | GSK452101 will be administered. |
| Niraparib | DRUG | Niraparib will be administered. |
Inclusion Criteria: * More than or equal to (≥)18 years of age * Eastern cooperative oncology group (ECOG) class 0-2 * Life expectancy of a minimum of 3 month * Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options (Part...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
GSK4524101 is an investigational small molecule being developed by GSK plc for the treatment of solid tumors. It is in Phase 1 clinical development and is being studied both as a monotherapy and in combination with niraparib in participants with neoplasms.
GSK4524101 is being studied for the treatment of neoplasms, specifically solid tumors. It is not yet approved for any indication and remains an investigational therapy in Phase 1 clinical development.
GSK4524101 is being developed by GSK plc, which trades under the ticker GSK. The company is the sponsor of the Phase 1 clinical trial evaluating the drug in participants with solid tumors.
GSK4524101 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency for any indication.
GSK4524101 is being evaluated in one active clinical trial, NCT06077877, titled a study to investigate the safety, tolerability, pharmacokinetics, and preliminary anticancer activity of GSK4524101 alone or with niraparib in participants with solid tumors. The trial is active but not recruiting, with an enrollment of 42 participants across the United States, Canada, and Panama.
Yes, the Phase 1 trial NCT06077877 for GSK4524101 is biomarker-selected, meaning participants are enrolled based on specific biomarker criteria. The study is randomized and active-controlled, evaluating the drug alone or in combination with niraparib in adults with solid tumors.